BioNTech SE

BNTXintermediary

BioNTech is a German biotechnology company that co-developed the first authorized mRNA COVID-19 vaccine with Pfizer. It is now leveraging its mRNA platform for individualized cancer vaccines, infectious disease programs, and cell therapies.

⇄ Compare

Produkte & Umsatz

Umsatzanteil nach Produkt

Umsatzaufschlüsselung ($4.8B)

Statische Daten (Echtzeitfinanzen werden geladen…)

COVID-19 Vaccine Revenue (68%)

Collaboration Revenue (Pfizer) (18%)

R&D Grants & Other (14%)

Segmentzusammensetzung und Hauptkunden

Produktdetails

Comirnaty (COVID-19 Vaccine)55%

mRNA-based COVID-19 vaccine developed with Pfizer

Oncology mRNA (BNT111, BNT122)15%

Individualized mRNA cancer vaccines targeting solid tumors

Infectious Disease Pipeline10%

mRNA vaccines for influenza, shingles, and malaria

Lieferkettenbeziehungen

Partner

Pfizer Inc.

Comirnaty COVID vaccine co-development

Auswirkung: Critical — Pfizer is primary commercialization partner

Wettbewerber

Moderna, Inc.

mRNA vaccines and oncology

Auswirkung: Primary mRNA competitor

Regeneron Pharmaceuticals

Cancer immunotherapy

Auswirkung: Competing in oncology

Makro- und Marktkontext

제약 / 바이오Sektornachrichten

GLP-1 메가트렌드 + AI 신약개발 + 저평가 바이오 기관 매집

GLP-1 시장 규모 (2030E)

$150B

mRNA 암백신 임상 성공률

+49% 재발 위험 감소

AI 신약개발 단계

임상 2상 진입

PFE/MRNA 52주 변화

-30% ~ -45%

Nächste Katalysatoren

◆LLY Orforglipron(경구용 GLP-1) 3상 결과 (2026.Q2)◆MRNA 암백신 FDA BLA 제출 예정◆REGN EYLEA HD 유럽 허가 결과

Aktuelle Nachrichten

Nachrichten laden...

KI-Analyse

Klicken Sie auf "KI-Analyse abrufen" für eine KI-gestützte Lieferkettenanalyse von BioNTech SE.

Unternehmensinformationen

Hauptsitz

Mainz, Germany

Gegründet

2008

Mitarbeiter

6,000+

Website

biontech.com

Sektorübersicht — 제약 / 바이오

Sektornachrichten